Cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib plus fulvestrant as first-line treatment in HR+/HER2-advanced breast cancer
{{output}}
Purpose: This study aims to evaluate the cost-effectiveness of inavolisib plus palbociclib-fulvestrant versus palbociclib-fulvestrant for treating advanced HR+/HER2-breast cancer patients with PIK3CA mutations from both United St... ...
